Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

NCT04981912 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventions

DRUG: HDMP + rituximab as a means of debulking prior to initiating venetoclax.

Sponsor

University of California, San Diego